Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
almitrine + raubasine
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Duxil is a fixed-dose combination of almitrine (a peripheral chemoreceptor agonist and respiratory stimulant) and raubasine (a vasoactive indole alkaloid with alpha-adrenolytic properties). Developed by Servier, Duxil is designed to improve oxygenation and blood flow to cerebral and neurosensory tissues. Almitrine acts on peripheral chemoreceptors in the carotid bodies to increase arterial oxygen tension, while raubasine acts as an alpha-1 adrenergic receptor antagonist to promote vasodilation and enhance microcirculation. This synergistic combination has been utilized for the treatment of age-related cognitive decline, vascular cognitive impairment, and functional rehabilitation after stroke. Although historically marketed in several countries, Duxil has been withdrawn in some regions, including France, due to safety concerns such as peripheral neuropathy and weight loss.
- Brand names
- AlbasineAruxilDuxarilTruxil
- Other names
- almitrine and raubasinealmitrine bismesylate + raubasinealmitrine bismesylate/raubasinealmitrine dimesylate + raubasinealmitrine dimesylate/raubasinealmitrine/raubasine
02
Targets
ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)HTR2A (5-hydroxytryptamine receptor 2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)
Beyond the preview
Go deeper on almitrine + raubasine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on almitrine + raubasine.